People will always help people and this App
is proof of our peer to peer support platform

What do we do?

What we do:

We build connections in the patient community worldwide. Chronic diseases pose a large socioeconomic burden on our society and the time to stop the progression of these diseases is now.

heart in hand

How do we do it:

Improving the quality of life of patients is critical in helping them manage their disease(s) better and avoiding the co-morbidities from occurring. By addressing the underlying factors of alienation, depression, and loneliness, we achieve better outcomes and improved quality of life for patients.

globe

Why do we exist:

Significant research is being done to find cures and vaccines for these diseases. However,  almost 80% of all healthcare spending is used in managing these chronic disease patients. Our objective is to provide a low cost solution to managing the quality of life for these patients, in effect, making them more adherent, better informed and healthier overall.

Meet our founders

Sunil Modi

CEO/CO-FOUNDER

Sunil has over 20 years of business leadership and I.T experience from major companies and startups.  He presently leads a team of software engineers, doctors, healthcare workers, marketers and bloggers at Reachout.  Sunil creates a challenging but collaborative environment that fosters a culture of innovation, team spirit, and personal growth.

Sunil believes that effectively managing chronic diseases has a far greater impact on the society than any innovation in medicine today.  Chronic disease patients can manage their conditions much more effectively given the right set of tools and measures to do so.  Together, patient power can and will achieve a greater quality of life.

Facebook icon blueTwitter SignLinkedIn Sign

Dr. Rashmi Jain

MED ADVISOR/CO-FOUNDER

Sunil’s wife and a pediatrician by trade, Rashmi has a thriving practice in Fort Worth, TX. Rashmi has over 10 years of patient care experience in dealing with chronic as well as acute conditions. Currently, she serves in the capacity of medical/disease advisor to the platform.

Advisory Board

Elizabeth Charlotte Moser MD PhD MSc MBA

Elizabeth Charlotte Moser (1973) is a radiation oncologist, health care director, advisor and a teacher in Cancer research & treatment. Her work has been focused on modern and targeted therapies, survivorship issues and costs efficiency of cancer care.

Read more

During 20 years of clinical practice, she actively took part in organizing multidisciplinary cancer care across different public and private hospitals in the West of France. This directly improved patient survival and hospitals profitability. She moved to Southwest Europe to co-lead the set-up of one of the biggest national cancer centers. Being part of this executive team, she has learned the essentials of a matrix structure advantages in multidisciplinary cancer institute. Since this center had achieved a maturity stage, she left to Boston where she just completed her MBA at the Massachusetts Institute of Technology (main electives: Finance, Startups legal aspects, Digital health and Web platforms) and at the same time deepened knowledge in translational research and drug development with a Master degree in Cancer Biology and Therapeutics Innovation at Harvard University. She graduated with valedictorian honors being top of her class. Besides being fluently in 5 languages, she now owns all pillars of health care leadership combining medical, management & finance and translational research expertise in innovative cancer care.

From January 2018, she works for Elekta Limited as Vice President Treatment Pathway Requirements and Usability, besides continuing her work as supervisory / executive board functions in various healthcare related companies like hospital networks, digital health providers, pharmaceutical, medical systems, investment firms and internal ventures.

Less

LinkedIn Sign

Marc L. Berger, MD

Marc L. Berger, MD, retired in July 2017 after serving five years as Vice President, Real World Data and Analytics (RWDnA) at Pfizer, Inc. During his career, Marc has held senior-level positions in the industry including Executive Vice President and Senior Scientist at OptumInsight; Vice President, Global Health Outcomes at Eli Lilly and Company; and Vice President, Outcomes Research and Management at Merck & Co., Inc. He currently serves as Chair of the Real World Evidence Advisory Board for SHYFT Analytics. During his career in the industry, he was involved with all aspects of drug development and commercialization including the design and execution of Phase 2/3/4 clinical trials, real world data studies, and market access strategies.

Read more

Marc earned his M.D. from Johns Hopkins University School of Medicine in Baltimore, Maryland. He has held adjunct appointments as Senior Fellow at the Leonard Davis Institute at the Wharton School of the University of Pennsylvania and Professor in the Department of Health Policy and Administration at the University of North Carolina at Chapel Hill School of Public Health.

During his career, Marc has served on the Medicare Evidence Development & Coverage Advisory Committee (MedCAC) for CMS, the steering committee for the AHRQ Centers for Research and Education on Therapeutics (CERTs), the board of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR), the Advisory Council for North America (ACNA) of the DIA, the editorial advisory board of Value in Health and has chaired the Innovative Technology Advocacy Committee of PhRMA.

Marc is also actively involved in promoting best practices for the leveraging of real world data to inform healthcare decision making.  He co-chaired the recent joint ISPOR-ISPE Task Force on enhancing the credibility of real-world evidence for decision making.  He also is a member of the Advisory Group for the Real-World Evidence Collaborative at the Duke-Margolis Center for Health Policy that will be holding workshops in 2018 on what constitutes quality in real world data and in what circumstances could real world evidence be considered substantial and therefore suitable for regulatory bodies to consider in making label changes.

Less

LinkedIn Sign

Pin It on Pinterest